biotech news today glp-1 This is working on a pill that could be better than the Wegovy version Chinese Biotech Takes Aim At

Integrate ongoing conversations about obesity as a chronic disease

The science behind the claims We always prioritise clinically supported information

J Neurogastroenterol Motil

Even companies like Amgen and Novartis, still in early or limited stages in this space, are investing heavily in metabolic disease pipelines, signaling that the race for dominance in obesity and diabetes therapeutics is far from over and will only intensify as global prevalence of these conditions continues to rise

In times of high economic uncertainty and an increasing cost of living, employers should ensure the well-being of their workers without hurting the businesss prosperity

Mixed results with GLP-1s With all the emerging data, theres still uncertainty about some of GLP-1's effects